Literatura
Časopisy s Impact faktorem
A - B - C - D - E - G - H - Ch - J - K - L - M - N - O - P - R - S - T - W -Z
Abstracts of The 7th Interscience World Conference
on Inflammation, Antirheumatics, Analgetics, Immunomodulators.
Geneva 1997. International Journal of Tissue Reactions
XIX (1/2): 86-99, 1997.
Impact factor: 0,444
Beuth J., Ost B.,
Pakdaman A., Rethfeldt E., Bock P.R., Hanisch J., Schneider B.:
Impact of complementary oral enzyme application on the postoperative
treatment results of breast cancer patients - results of an epidemiological
multicentre retrolective cohort study. Cancer Chemotherapy and Pharmacology
47: S45-S54, 2001.
Impact factor: 1,928 Onk-129
Calnan, J.: The prevention of post-operative
oedema. Controlled clinical trial of lyophilised chymotrypsin in plastic
surgery. Brit. Med. J. 261-263, 1960.
Dale
P.S., Tamhankar Ch.P., George D., Daftary G.V.: Co-medication
with hydrolytic enzymes in radiation therapy of uterine cervix: evidence
of the reduction of acute side effects. Cancer Chemotherapy and Pharmacology
47: S29-S34, 2001. Onk-3
Derveniece A., Hartmane I., Mikazans
I., Rozniece K., Ivdra I. : Aciclovir and Wobenzym combination
in treatment of genital herpes.International Journal of STD and AIDS
13 (suppl. 1); 42 (2002).
Impact factor: 1,394
Desser L,
Herbacek l., Závadová E., Mohr T.:
Conversion of α2-Macroglobulin (α2-M) to the fast-form by Wobenzym®
interrupts the autocrine loop of TGF-β production in melanoma cells.
The European Journal of Cancer 35 (4): No. 1526, 375, 1999.
Impact factor: 3,562 Onk-79
Desser L, Holomanova D., Závadová E., Pavelka K., Mohr T., Herbacek I.: Oral therapy with proteolytic enzymes decreases excessive TGF-β levels in human blood. Cancer Chemotherapy and Pharmacology 47: S10-S15, 2001. Imun-25
Desser
L., Rehberger A., Kokron E., Paukovits W.:
Cytokine synthesis in human peripheral blood mononuclear cells after
oral administration of polyenzyme preparations. Oncology 50: 403-407,
1993.
Impact factor: 2,141 Imuno-26
Desser
L., Sakalová A., Závadová E., Holomanova D., Mohr T.:
Concentrations of soluble tumor necrosis factor receptors, β2-microglobulin,
IL-6 and TNF in serum of multiple myeloma patients after chemotherapy
and after combined enzyme + chemotherapy. International Journal of Immunotherapy
XIII (3/4): 121-130, 1997.
Impact factor: 0,172 Exp-22
Desser L., Zavadova E., Herbacek I.:
Oral enzymes as additive cancer therapy. Int.J.Immunotherapy XVII(2/3/4)
153-161 (2001).
Impact factor: 0,242
Dosenkov V.E., Zaharova V.P., Byts
Y.V. : Systemic enzyme therapy in experimental atherosclerosis.
Int.J.Immunotherapy XVII(2/3/4) 51-58 (2001).
Impact factor: 0,242
Dušková
M., Wald M.: Orally administered
proteases in aesthetic surgery. Aesthetic Plastic Surgery 23 (1): 41-4,
1999.
Impact factor: 0,366 CH-25
Emancipator
S.N., Chintalacharuvu S.R., Urankar Nagy N., Petersilge C., Stauder
G.: Effects of oral enzymes
in collagen II induced arthritis in mice. International Journal of Immunotherapy
XIII (3/4): 67-74, 1997.
Impact factor: 0,172 Exp-27
Emancipator
S.N., Chintalacharuvu S.R., Urankar Nagy N., Stauder G.:
Oral enzymes in different animal models of glomerulonephritis. International
Journal of Immunotherapy XIII (3/4): 97-103, 1997.
Impact factor: 0,172 Exp-25
Ernst E.: Oral therapy with
proteolytic enzymes: Effects on hemorheological parameters.
Perfusion 12: 440-441, 1994.
Impact factor: 0,534
Gaciong
Z., Paczek L, Bojakowski K., Socha K., Wisniewski M., Heidland A.:
Beneficial effect of proteases on allograft arteriosclerosis in a rat
aortic model. Nephrology Dialysis Transplantation 11 (6): 987-989, 1996.
Impact factor: 1,628 Exp-29
Garbin F.,
Harrach T., Eckert K., Maurer M.:
Bromelain proteinase F9 augments human lymphocyte-mediated growth inhibition
of various tumor cells in vitro. International Journal of Oncology 5:
197-203, 1994.
Impact factor: 1,181 Exp-31
Gebauer
F., Micheel B., Stauder G., Ransberger K., Kunze R.:
Proteolytic enzymes modulate the adhesion molecule CD44 on malignant
cells in vitro. International Journal of Immunotherapy XIII (3/4): 111-119,
1997.
Impact factor: 0,172 Exp-32
Gesualdo
L, Ricanati S., Medhat 0. Hassan, Emancipator S.N., Lamn M.E.:
Enzymolysis of glomerular immune deposits in vivo with dextranase/protease
ameliorates proteinuria, hematuria, and mesangial proliferation in murine
experimental IgA nephropathy. Journal of Clinical Investigation 86:
715-722, 1990.
Impact factor: 9,667 Far_mech-14
Guangsheng X., Schinzel R., Simm A.,
Sebekova K., Heidland A.: Advanced glycation end products impair
protein turnover in LLC-PK1: Amelioration by trypsin. Kidney International,
Vol. 59, Suppl. 78 (2001), pp. S-53 - S-57.
Impact factor: 5,016
Gujral
M.S., Patnaik P.M., Kaul R., Daftary G.V., Parikh H.K., Tamhankar C.P.,
Schiess W.:
Oral enzymes preventing side effects of radiation therapy in patients
with head and neck cancers. The European Journal of Cancer 35 (4): No.
543, 168, 1999.
Impact factor: 3,562 Onk-8
Gujral
M.S., Patnaik P.M., Kaul R., Parikh H.K., Conradt Ch., Tamhankar Ch.P.,
Daftary G.V.:
Efficacy of hydrolytic enzymes in preventing radiation therapy-induced
side effects in patients with head and neck cancers. Cancer Chemotherapy
and Pharmacology 47: S23-S28, 2001.
Impact factor: 1,928 Onk-8
Hall S.W., LaMarre J., Marshall L.B.,
Hayes M.A., Gonias S.L: Binding of transforming growth factor-beta
1 to methylamine-modified alpha 2-macroglobulin and to binary and ternary
alpha 2-macroglobulin-proteinase complexes. Biochem J (2): 569-575,
1992.
Hale L.P.,
Haynes B.F.: Bromelain treatment
of human T cells removes CD44, CD45RA, E2/MIC2, CD6, CD7, CDS, and Leu
8/LAM1 surface molecules and markedly enhances CD2-mediated T cell activation.
Journal of Immunology 149 (12): 3809-3816, 1992.
Impact factor: 6,937 Exp-35
Harrach T.,
Gebauer F., Eckert K., Kunze R., Maurer H.:
Bromelain proteinases modulate CD44 expression on human Molt 4/8 leukemia
and SK- Mel 28 melanoma cells in vitro. International Journal of Oncology
5: 485-488, 1994.
Impact factor: 1,181 Exp-36
Heidland
A., Sebekova K., Paczek L., Teschner M., Dammrich J., Gaciong Z.:
Renal fibrosis: Role of impaired proteolysis and potential therapeutic
strategies. Kidney International 52 (62): 32-35, 1997.
Impact factor: 4,071 Exp-38
Heinz H.P., Loos M.: Activation
of the first component of complement, Cl: comparison of the effect of
16 different enzymes on serum Cl. Immunobiology 165: 175-185, 1983.
Impact factor: 1,378
Heumann
D., Vischer T.L: Immunomodulation by alfa2-macroglobulin-proteinase
complexes: the effect on the human T lymphocyte response. European Journal
of Immunology 18: 755-760, 1988.
Impact factor: 5,256 Exp-39
Chintalacharuvu S.R., Uranakr-Nagy N., Petersilge
CH.A., Abdul-Karim F.W., Emancipator S.N.: Treatment of collagen
induced arthritis by proteolytic enzymes: immunomodulatory and disease
modifyng effects. The Journal of Rheumatology 28 (9); 2049-2059 (2001).
Impact factor: 2,987
James K.:
Interactions between cytokines and alfa2-macroglobulin. Immunology Today
11: 163-166, 1990.
Impact factor: 16,465 Far_mech-20
Jutila
et al., Low-dose chymotrypsin treatment inhibits neutrophil
migration into sites of inflammation in vivo: effects on Mac-1 and MEL-14
adhesion protein expression and function.
Cellular Immunology. 132, pp. 201-214 (1991). Exp-40
Kafková H., Kojanová M.: Lymfedém.
Posgraduální medicína 5 (6); 626-633 (2003).
Impact factor: 1,394
Khryanin A.A., Lykova S.G.:
Oral enzymes improve the efficacy of Chlamydia trachomatis infection
treatment.International Journal of STD and AIDS 13 (suppl. 1); 41,2002.
Impact factor: 1,394
Kleef R.,
Delohery T.M., Bovbjerg D.H.:
Selective modulation of cell adhesion molecules on lymphocytes by bromelain
protease 5. Pathobiology 64: 339-346, 1996.
Impact factor: 0,652 Exp-43
Klein
G., Kullich W.: Kurzzeitbehandlung mit oralen Enzymen bei
schmerzhafter Osteoarthrose des Knies. Clin Drug Invest 19 (1): 15-23,
2000.
Impact factor: 0,914 R-5
Kokron E., Rehberger A., Desser L.:
Influence of cytokines and proteolytic enzymes on the expression of
vitronectin-receptor (VNR) in human melanoma cells. Journal of Cancer
Research and Clinical Oncology 118: 117, 1992.
Koshkin V.M., Kirienko A.I.:
Systemic enzyme therapy in the treatment of acute thrombosis of superficial
veins in the lower extremites and postthrombophlebitic disease. Int.J.Immunotherapy
XVII(2/3/4) 121-124,2001.
Impact factor: 0,242
Kovalenko V., Shuba N.M., Golovatskiy
I.V., Bortkevich O.P.: Estimation of efficacy of basic therapy
of rheumatoid arthritis on the basis of systemic enzyme therapy:Results
of five-year monitoring. Int.J:Immunotherapy XVII(2/3/4)129-133, 2001.
Impact factor: 0,242
Kovalenko V., Sledzevskaya I.K., Ryabokon
E.N., Gavrilenko T.I.: New aproaches to modern cardiology based
on systematic enzyme therapy. Int.J.Immunotherapy XVII(2/3/4) 101-111,
2001.
Impact factor: 0,242
Lackovic
V., Rovensky J., Horvathova M., Malis F.: Interferon production
in whole blood cultures from volunteers and rheumatoid arthritis patients
after medication with oral enzymes. International Journal of Immunotherapy
XIII (3/4): 159-165, 1997.
Impact factor: 0,172 R-36
Lauer
D., Müller R., Cott Ch., Otto A., Naumann M., Birkenmeier G.:
Modulation of growth factor binding properties of α2-macroglobulin by
enzyme therapy. Cancer Chemotherapy and Pharmacology 47: S4-S9, 2001.
Impact factor: 1,928 Far_mech-30
Lauer
D., Reichenbach A., Birkenmeier G.: α2-makroglobulin-mediated
degradation of amyloid βl-42: mechanism to enhace amyloid β catabolism.
Experimental Neurology 167: 385-392, 2001.
Impact factor: 3,641 Far_mech-31
Lehmann P.V.: Immunomodulation
by proteolytic enzymes. Nephrology Dialysis Transplantation 11 (6):
953-955, 1996.
Impact factor: 1,682
Madar J., Ulcova-Gallova Z., Sula K.,
Kucera E., Peknicova J., Chaloupkova A., Nouza K., Kinsky R.:
Immunopathological Mechanisms in recurrent miscarriage and preeclampsoia.
American Journal of Reproductive Immunology 46 (1); 96 (2001).
Impact factor: 1,413
Malook S.G., Pravas P.M., Rashmi K.,
Hemen K.P., Conradt Ch., Tamhankar Ch.P., Daftary G.V.: Efficacy
of hydrolytic enzymes in preventing radiation therapy-induced side effects
in patients with head and neck cancers. Cancer Chemother Pharmacol 47.;
2001.
Impact factor: 1,928.
Manhart N., Akomeah R., Bergeister
H., Spittler A., Ploner M., Roth E.: Administration of proteolytic
enzymes bromelain and trypsin diminish the number of CD4+ cells and
the interferon-γ response in Peyer's patches and spleen in endotoxemic
balb/c mice.Cellular Immunology 215; 113-119 (2002).
Impact factor: 1,988
Maurer H.R.: Bromelain: biochemistry,
pharmacology and medical use. CMLS, Cell. Mol. Life Sci. 58; 1234-1245
(2001).
Impact factor: 5,259
May C., Smola M., Ruda C., Scharnagl
E.: Randomized open controlled clinical study on the efficacy
and tolerance of an oral enzyme preparation in lymphadenectomy patients.
Int.J.Immunotherapy XVII(2/3/4) 149-152 (2001).
Impact factor: 0,242
Mazurov V.I., Lila A.M.:
Optimization of reactive arthritis treatment using systemic enzyme therapy.
Int.J.Immunotherapy XVII(2/3/4) 125-128 (2001).
Impact factor: 0,242
Mazourov
V.I., Lila A.M., Klimko N.N., Raimuev K.V., Makulova T.G.:
The efficacy of systemic enzyme therapy in the treatment of rheumatoid
arthritis. International Journal of Immunotherapy XIII (3/4): 85-91,
1997.
Impact factor: 0,172 R-7
Menssen H.D., Sakalová A., Fontana
A., Herman Z., Boewer Z., Facon T., Lichinister M.R., Singer C.R.J.,
Euller-Ziegler L., Wetterwald M., Fiere D., Hrubisko M., Thiel E., Delmas
P.D.: Effects of long term intravenous ibandronate therapy
on skeletal-related events, survial, and bone resorption markers in
patients with advanced multiple myeloma.Journal of Clinical Oncology
20 (9); 2353-2359 (2002).
Impact factor: 9,868
Mohr T.,
Závadová E., Hauptmann E., Maca S., Neumann M., Salzer H., Micksche
M.:
Modulation of human tumor associated macrophages from malignant effusions
with cytokines and proteolytic enzymes. The European Journal of Cancer
35 (4): No. 1448, 357, 1999.
Impact factor: 3,562 Far_mech-35
Moore, F.T.: A report on seventy-five patients treated with Chymar (lyophilised chymotrypsin). Brit. J. plast. Surg. : 335-339, 1962.
Mudrák
J., Bobák L., Šebová I.: Adjuvant Therapy with Hydrolytic
Enzymes in Recurrent Laryngeal Papillomatosis. Acta Oto-Laryngologica
(Stockh) 527: 128-130, 1997.
Impact factor: 0,603 ORL-16
Munzig E., Eckert K., Harrach T.,
Graf H., Maurer H.R.: Bromelain protease F9 reduces the CD44
mediated adhesion of human peripheral blood lymphocytes to human umbilical
vein endothelial cells. FEBS Letters 351: 215-218, 1994.
Impact factor: 3,504
Nakazawa M., Emancipator
S.N., Lamn M.E.: Proteolytic
enzyme treatment reduces glomerular immune deposits and proteinuria
in passive Heymann nephritis. Journal of Experimental Medicine 164:
1973-1987, 1986.
Impact factor: 14,384 Nefro-19
Nouza K., Madar J.:
Immunomodulation in the treatment of reproduction disturbances. American
Journal of Reproductive Immunology 46 (1); 106 (2001).
Impact factor: 1,413 Gyn-20
Nortier J. et al., Enzymatic degradation of tumor necrosis factor by activated human neutrophils: role of elastase. Life Sci., 49, 25, 1991
Österreicher J., Škopek J., Navrátil L., Knížek
J., Šebková V., Máčela A.: Enteral administration of proteinase
mixture inhibits development of postradiation pneumonitis and lung fibrosis
in rats. Int. J. Immunotherapy XVII (2/3/4): 51-58, 2001.
Impact factor: 0,242
Popiela
T., Kulig J., Hanisch J., Bock P.R.: Influence of a complementary
treatment with oral enzymes on patients with colorectal cancers - an
epidemiological retrolective cohort study. Cancer Chemotherapy and Pharmacology
47: S55-S63, 2001.
Impact factor: 1,928 Onk-26
Rovenská E., Švík K., Stančíková M., Rovenský
J.: Inhibitory effect of enzyme therapy and combination therapy
with cyclosporin A on collagen-induced arthritis. The Journal of Rheumatology
28 (supplement 63); 91 (2001).
Impact factor: 2,987
Sakalová
A., Bock P.R., Dědík L., Hanisch J., Schiess W., Gážová S., Chabroňová
l., Holomanova D., Mistrík M, Hrubiško M.:
Retrolective cohort study of an additive therapy with an oral enzyme
preparation in patients with multiple myeloma. Cancer Chemotherapy and
Pharmacology 47: S38-S44, 2001.
Impact factor: 1,928 Onk-28
Sakalova A., Desser L., Závadová E.,
Holomanova D., Mohr T.: Enzyme therapy improved remission time,
soluble TNF- receptors and β2-microglobulin concentration in chemotherapy
treated multiple myeloma patients. British Journal of Haematology 102
(1): 353, 1998.
Impact factor: 3,370
Saradeth
T., Quittan M., Ghanewm A.H., Ernst E.:
Improvement in blood fluidity characteristics via Phlogenzym - An in
vitro pilot study. Perfusion 6: 196-198, 1995.
Impact factor: 0,534 Angio-50
Schedler M., Lind A., Schätzle W., Stauder G.: Adjuvant therapy with hydrolytic enzymes in oncology - a hopeful effort to avoid bleomycinum induced pneumotoxicity? Journal of Cancer Research and Clinical Oncology 116: 697, 1990.
Šebeková
K., Dämmrich J., Fierlbeck W., Krivošíková Z., Paczek L, Heidland A.:
Systemic treatment with proteolytic enzymes in rat models of nonimmune
mediated renal diseases. International Journal of Immunotherapy XIII
(3/4): 79-83, 1997.
Impact factor: 0,172 Exp-59
Šebeková
K., Dämrich J., Fierlbeck W., Krivosiková Z., Paczek L. Heidland A.:
Effect of chronic therapy with proteolytic enzymes on hypertension induced
renal injury in the rat model of goldblatt hypertension. The American
Journal of Nephrology 18; 570-576 (1998).
Impact factor: 1,476 Exp-58
Šebeková
K., Dämmrich J., Krivosiková Z., Heidland A.: The effect
of oral protease administration in the rat remnant kidney model. Res
Exp Med 199: 177-188, 1999.
Impact factor: 1,194 Exp-60
Shaikov A.V., Movsisyan G.R., Stolyarova
A.V.: Wobenzym in the treatment of patients with juvenile chronic
arthritis. International Journal of Immunotherapy XIII (3/4): 93-96,
1997.
Impact factor: 0,172
Singer F., Singer C., Oberleitner
H.: Phlogenzym versus diclofenac in the treatment of activited
osteoarthritis of the knee. A double-blind prospective randomized study.
Int.J.Immunotherapy XVII(2/3/4) 135-141, 2001.
Impact factor: 0,242
Skutelis A., Pule E., Purvins I.,
Baltkajs J., Skromanis M., Zeibarts M., Desser L., Österreicher J, Ansbergs
J.: Phlogenzym may prevent metabolic injures to myocardium.
Results of a laboratory experiment with rats. Int.J.Immunotherapy XVII(2/3/4)
59-64, 2001.
Impact factor: 0,242
Solyanik G.I., Todor I.N., Yurchenko
O.V., Ponomareva O.V., Banakhevych N.V., Terzov A.I., Chekhun V.F.:
Reduction of cisplatin-induced nephrotoxicity by proteolytic enzymes
in tumor-bearing rats. Int.J.Immunotherapy XVII(2/3/4) 75-81, 2001.
Impact factor: 0,242
Stauder
G., Donnerstag B., Baumhackl U., Buschmans E.:
Use of oral enzymes in multiple sclerosis: Phenotyping of peripheral
blood lymphocytes from MS patients under long-term treatment with orally
administered hydrolytic enzymes. International Journal of Immunotherapy
XIII (3/4): 135-137, 1997.
Impact factor: 0,172 Neur-12
Stauder G., Kabil S.: Oral
enzyme therapy in hepatitis C patients. International Journal of Immunotherapy
XIII (3/4): 153-158, 1997.
Impact factor: 0,172
Suchich
G.T., Loginova N.S., Faizullin L.Z., Zdanov A.V., Malinina E.V., Bozedomov
V. A.:
The use of Wobenzym® to facilitate interferon synthesis in the treatment
of chronic urogenital chlamydiosis. International Journal of Immunotherapy
XIII (3/4): 131-133, 1997.
Impact factor: 0,172 G-22
Sy M.S.,
Liu D., Kogerman P., Culp L.A.: Potential of targeting
cell surface CD44 proteins with proteinases in preventing tumor growth
and metastasis. International Journal of Immunotherapy XIII (3/4): 105-109,
1997.
Impact factor: 0,172 Exp-70
Trevani A.S.,
Andonegui G., Giordano M., Nociari M., Fontán P, Dran G., Geffner J.
R.:
Neutrophil Apoptosis Induced by Proteolytic Enzymes. Laboratory Investigation
74 (3): 711-721,1996.
Impact factor: 4,653 Obec-14
Wald M.,
Olejár T., Poučková P., Zadinova M.:
Proteinases reduce metastatic dissemination and increase survival time
in C57BI6 mice with the Lewis lung carcinoma. Life Sciences 63 (17):
237-243, 1998.
Impact factor: 2,275 Exp-76
Wald M.,
Olejár T., Poučková P., Zadinova M.:
The influence of proteinases on in vivoblastic transformation in rat
species SD/lpcv with spontaneous lymphoblastic leukemia.
British Journal of Haematology 102 (1): 294, 1998.
Impact factor: 3,370 Exp-77
Wald
M., Olejar T., Šebková V., Zadinova M., Boubelík M., Poučková P.:
Mixture of trypsin, chymotrypsin and papain reduces formation of metastases
and extends survival time of C57BI6 mice with syngeneic melanoma B16.
Cancer Chemotherapy and Pharmacology 47: S16-S22, 2001.
Impact factor: 1,928 Onk-120
Wald
M., Poučková P., Hloušková D., Altnerová M., Olejár T.:
The influence of trypsin, chymotrypsin and papain on the growth of human
pancreatic adenocarcinoma transplanted to nu/nu mice. The European Journal
of Cancer 35 (4): No. 543, 148, 1999.
Impact factor: 3,562 Exp-79
Wald M.,
Závadová E., Poučková P., Zadinova M., Boubelík M.:
Polyenzyme preparation Wobe-Mugos® inhibits growth of solid tumors and
development of experimental metastases in mice. Life Sciences 62 (3):
43-48, 1998.
Impact factor: 2,275 Exp-82
Wiest-Ladenburger
U., Richter W., Moeller P., Boehm B.O.: Protease treatment
delays diabetes onset in diabetes-prone nonobese diabetic (NOD) mice.
International Journal of Immunotherapy XIII (3/4): 75-78, 1997.
Impact factor: 0,172 Exp-85
Wittenborg,
Bock P.R., Hanisch J., Sailer R., Schneider B.: Comparative
epidemiological study in patients with rheumatic diseases illustrated
in an example of a treatment with non-steroidal anti-inflammatory drugs
versus an oral enzyme combination. Drug Research 50 (8): 728-738, 2000.
Impact factor: 0,914 R-20
Wood G.R.,
Ziska T., Morgenstern E., Stauder G.: Sequential effects
of an oral enzyme combination with rutosid in different in vitro and
in vivo models of inflammation. International Journal of Immunotherapy
XIII (3/4): 139-145, 1997.
Impact factor: 0,172 Exp-87
Zänker K.S.: The use of systemic
enzyme therapy in oncology. Cancer Chemotherapy and Pharmacology 47:
S1-S3, 2001.
Impact factor: 1,928
Závadová
E., Desser L, Mohr T.: Stimulation of reactive oxygen species
production and cytotoxicity in human neutrophils in vitro and after
oral administration of a polyenzyme preparation. Cancer Biotherapy 10
(2): 147-152, 1995.
Impact factor: 0,781 Exp-92
Závadová E., Desser L: Proteolytic
enzymes stimulate the cytotoxic activity of human granulocytes in vitro
and in vivo. International Journal of Immunotherapy XIII (3/4): 147-151,
1997.
Impact factor: 0,172
Závadová E., Loercher A., Verstovsek
S., Verschraegen C., Micksche M., Freedman R.S.: The role of
macrophages in antitumor defense of patients with ovarian cancer. Hematology/Oncology
Clinics of North America 1 (13): 135-144, 1999.
Impact factor: 2,096
Závadová E., Savary C., Freedman R.S.:
Maturation of dendritic cells (D.C.) from ovarian cancer patients. Clinical
Cancer Res. 5 (152), 1999.
Impact factor: 5,991
Zavadova
E., Savary Ch.A., Templin S., Verschraegen C.F., Freedmann R.S.:
Maturation of dendritic cells from ovarian cancer patients. Cancer Chemother
Pharmacol (2001) 48: 289-296.
Impact factor: 1,928 Exp-92
Lék pro vnitřní užití. Čtěte pečlivě příbalovou
informaci.
Inzertní stránky společnosti MUCOS Pharma CZ, s.r.o. - tel: (+420)-267 750
003